nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—SLC6A3—Gilles de la Tourette syndrome	0.566	0.635	CbGaD
Duloxetine—HTR2A—Gilles de la Tourette syndrome	0.325	0.365	CbGaD
Duloxetine—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00761	0.168	CbGeAlD
Duloxetine—HTR2A—autonomic nervous system—Gilles de la Tourette syndrome	0.00457	0.101	CbGeAlD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00444	0.0725	CbGpPWpGaD
Duloxetine—NPY1R—nervous system—Gilles de la Tourette syndrome	0.00283	0.0626	CbGeAlD
Duloxetine—NPY1R—central nervous system—Gilles de la Tourette syndrome	0.00273	0.0603	CbGeAlD
Duloxetine—NPY1R—brain—Gilles de la Tourette syndrome	0.00217	0.0479	CbGeAlD
Duloxetine—HTR6—nervous system—Gilles de la Tourette syndrome	0.00199	0.0441	CbGeAlD
Duloxetine—HTR6—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.00199	0.0325	CbGpPWpGaD
Duloxetine—HTR6—central nervous system—Gilles de la Tourette syndrome	0.00192	0.0424	CbGeAlD
Duloxetine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00183	0.0298	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00164	0.0267	CbGpPWpGaD
Duloxetine—HTR6—brain—Gilles de la Tourette syndrome	0.00152	0.0337	CbGeAlD
Duloxetine—HTR2C—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.00146	0.0239	CbGpPWpGaD
Duloxetine—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.00145	0.0321	CbGeAlD
Duloxetine—HTR2C—midbrain—Gilles de la Tourette syndrome	0.0014	0.031	CbGeAlD
Duloxetine—SLC6A4—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.0014	0.0229	CbGpPWpGaD
Duloxetine—HTR6—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0014	0.0228	CbGpPWpGaD
Duloxetine—HTR6—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00136	0.0221	CbGpPWpGaD
Duloxetine—SLC6A4—midbrain—Gilles de la Tourette syndrome	0.00133	0.0294	CbGeAlD
Duloxetine—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00127	0.0207	CbGpPWpGaD
Duloxetine—HTR6—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00126	0.0206	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00121	0.0197	CbGpPWpGaD
Duloxetine—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.0012	0.0197	CbGpPWpGaD
Duloxetine—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.00119	0.0264	CbGeAlD
Duloxetine—HTR6—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00118	0.0192	CbGpPWpGaD
Duloxetine—HTR2C—nervous system—Gilles de la Tourette syndrome	0.00115	0.0255	CbGeAlD
Duloxetine—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.00115	0.0254	CbGeAlD
Duloxetine—HTR6—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00114	0.0186	CbGpPWpGaD
Duloxetine—HTR2C—central nervous system—Gilles de la Tourette syndrome	0.00111	0.0245	CbGeAlD
Duloxetine—SLC6A4—nervous system—Gilles de la Tourette syndrome	0.00109	0.0242	CbGeAlD
Duloxetine—HTR6—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00106	0.0173	CbGpPWpGaD
Duloxetine—SLC6A4—central nervous system—Gilles de la Tourette syndrome	0.00105	0.0233	CbGeAlD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00105	0.0171	CbGpPWpGaD
Duloxetine—Atomoxetine—SLC6A3—Gilles de la Tourette syndrome	0.00104	0.405	CrCbGaD
Duloxetine—HTR2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00103	0.0168	CbGpPWpGaD
Duloxetine—HTR2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000999	0.0163	CbGpPWpGaD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.000973	0.0159	CbGpPWpGaD
Duloxetine—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.000962	0.0213	CbGeAlD
Duloxetine—HTR2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000931	0.0152	CbGpPWpGaD
Duloxetine—Fluoxetine—HTR2A—Gilles de la Tourette syndrome	0.000927	0.362	CrCbGaD
Duloxetine—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.000926	0.0205	CbGeAlD
Duloxetine—SLC6A3—brain—Gilles de la Tourette syndrome	0.000912	0.0201	CbGeAlD
Duloxetine—HTR2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000894	0.0146	CbGpPWpGaD
Duloxetine—HTR6—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000885	0.0144	CbGpPWpGaD
Duloxetine—HTR2C—brain—Gilles de la Tourette syndrome	0.000881	0.0195	CbGeAlD
Duloxetine—HTR2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000868	0.0142	CbGpPWpGaD
Duloxetine—HTR2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000865	0.0141	CbGpPWpGaD
Duloxetine—HTR2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00084	0.0137	CbGpPWpGaD
Duloxetine—SLC6A4—brain—Gilles de la Tourette syndrome	0.000835	0.0185	CbGeAlD
Duloxetine—HTR2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000808	0.0132	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000788	0.0129	CbGpPWpGaD
Duloxetine—HTR2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000783	0.0128	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000765	0.0125	CbGpPWpGaD
Duloxetine—HTR2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000751	0.0123	CbGpPWpGaD
Duloxetine—HTR6—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000744	0.0121	CbGpPWpGaD
Duloxetine—SLC6A2—brain—Gilles de la Tourette syndrome	0.000735	0.0163	CbGeAlD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000731	0.0119	CbGpPWpGaD
Duloxetine—HTR2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000729	0.0119	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000713	0.0116	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00071	0.0116	CbGpPWpGaD
Duloxetine—HTR2A—midbrain—Gilles de la Tourette syndrome	0.000703	0.0155	CbGeAlD
Duloxetine—HTR2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00068	0.0111	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000661	0.0108	CbGpPWpGaD
Duloxetine—HTR2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000652	0.0106	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000627	0.0102	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000608	0.00993	CbGpPWpGaD
Duloxetine—Atomoxetine—HTR2A—Gilles de la Tourette syndrome	0.000595	0.233	CrCbGaD
Duloxetine—HTR2A—nervous system—Gilles de la Tourette syndrome	0.000578	0.0128	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000567	0.00925	CbGpPWpGaD
Duloxetine—HTR2A—central nervous system—Gilles de la Tourette syndrome	0.000557	0.0123	CbGeAlD
Duloxetine—HTR2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000548	0.00894	CbGpPWpGaD
Duloxetine—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.000527	0.0116	CbGeAlD
Duloxetine—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000507	0.0112	CbGeAlD
Duloxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000496	0.0081	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000477	0.00779	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000463	0.00756	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000463	0.00756	CbGpPWpGaD
Duloxetine—HTR2A—brain—Gilles de la Tourette syndrome	0.000442	0.00977	CbGeAlD
Duloxetine—NPY1R—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000431	0.00704	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000416	0.00679	CbGpPWpGaD
Duloxetine—CYP2D6—brain—Gilles de la Tourette syndrome	0.000403	0.0089	CbGeAlD
Duloxetine—HTR2A—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.000397	0.00648	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000397	0.00648	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.000385	0.00629	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000358	0.00584	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00035	0.00571	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00034	0.00554	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000316	0.00516	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000302	0.00493	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000271	0.00443	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00027	0.0044	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00027	0.0044	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000262	0.00427	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000262	0.00427	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000245	0.004	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000244	0.00398	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000244	0.00398	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000238	0.00388	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000231	0.00377	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000225	0.00368	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000224	0.00366	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000221	0.00361	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000209	0.00341	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000199	0.00324	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000193	0.00315	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00018	0.00293	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000176	0.00287	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000173	0.00282	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000171	0.00279	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000171	0.00279	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000171	0.00279	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00017	0.00278	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000167	0.00273	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000165	0.0027	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000163	0.00266	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000159	0.0026	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000156	0.00255	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000155	0.00253	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000154	0.00251	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000148	0.00241	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000146	0.00239	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000146	0.00238	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000145	0.00236	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000143	0.00234	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00014	0.00229	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000134	0.00218	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000131	0.00213	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00013	0.00212	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000126	0.00205	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000126	0.00205	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000117	0.00191	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000115	0.00187	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000113	0.00184	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000111	0.00182	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000109	0.00178	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000108	0.00176	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000102	0.00166	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	9.95e-05	0.00162	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	9.66e-05	0.00158	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.16e-05	0.0015	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	9.03e-05	0.00147	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	9e-05	0.00147	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	8.77e-05	0.00143	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	8.21e-05	0.00134	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	8.17e-05	0.00133	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	7.32e-05	0.0012	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	7.11e-05	0.00116	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	6.65e-05	0.00109	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	6.62e-05	0.00108	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	6.46e-05	0.00105	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	6.4e-05	0.00104	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.36e-05	0.00104	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	6.3e-05	0.00103	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	6.17e-05	0.00101	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.02e-05	0.000982	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.78e-05	0.000943	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.75e-05	0.000939	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	5.72e-05	0.000934	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.61e-05	0.000915	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	5.42e-05	0.000884	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.34e-05	0.000871	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.22e-05	0.000852	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.18e-05	0.000845	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.83e-05	0.000787	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.64e-05	0.000757	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.21e-05	0.000688	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.93e-05	0.000641	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.81e-05	0.000622	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.55e-05	0.00058	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.41e-05	0.000557	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.38e-05	0.000552	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.31e-05	0.000541	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.09e-05	0.000504	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.49e-05	0.000406	CbGpPWpGaD
